Особенности клинико-эндокринологического статуса пациенток с генетически детерминированным риском развития рака органов женской репродуктивной системы
Диссертация
Одним из важных направлений современных научно-прикладных исследований РОЖРС является изучение эндокринных аспектов его этиологии и патогенеза. Известно, что опухоли органов женской репродуктивной системы тесно связаны с функцией эндокринных желез. При нарушении гормонального баланса в этих органах происходят процессы гиперплазии и малигнизации. По-видимому, стероидные гормоны оказывают влияние… Читать ещё >
Список литературы
- Акуленко Л.В. Клинико-генеалогическое и популяционно-статистическое исследование злокачественых новообразований яичников: Автореф. дис. канд. мед. наук. Москва, 1985.
- Бохман Я.В. Лекции по онкогинекологии. Ташкент: Медицина, 1985.-С. 39−58.
- Бохман Я.В. Новые подходы к лечению онкологического рака. -Санкт-Петербург, 1993. С. 15−39.
- Двойрин В.В., Аксель Е. М., Трапезников Н. Н. Заболеваемость злокачественными заболеваниями и смертность от них населения стран СНГ в 1995 году. // МОНЦ РАМН 1996. — 286 с.
- Дильман В.М. Эндокринологическая онкология. Ленинград: Медицина, 1983.-408 с.
- Козаченко А.В. Клинико-эндокринологические особенности миомы матки у женщин позднего репродуктивного и пременопаузального возраста. Дис.. канд. мед. наук. Москва, 1996.
- Котов Ю.Б. Программа наглядного анализа числовых таблиц. -Препринт ИПМ АН СССР. 1988. — № 123. — 29 с.
- Котов Ю.Б. Программа симптомного анализа. Препринт ИПМ АН СССР. — 1990. — № 58. — 26 с.
- Ю.Нефедов М. Д. Роль и характер наследственного предрасположения в развитии рака молочной железы. Автореф. дис.. канд. мед. наук. Москва, 1987.
- П.Сметник В. П., Кушлинский Н. Е., Чернуха Г. Е. Антиэстрогенная терапия при гиперплазии эндометрия. // Тезисы докладов Второго Российского научного конгресса «Человек и лекарство». Москва, 1995. -С. 156.
- Чимитдоржиева Т.Н. Особенности клинического течения семейного рака яичников: Автореф. дис.. канд. мед. наук. Москва, 1998.
- Adami Н.О., Hsieh С.С., Lamber M. et al. Parity, age at first childbirth and risk of ovarian cancer. // Lancet. 1994. — Vol. 344. — P. 1250−1254.
- Anderson D C. Sex-hormone-binding globulin. // Clin. Endocrinol. (Oxf) 1974. — Vol. 3. — P. 69−96.
- Auranen A., Grenman S., Kleml P.J. Immunohistochemically detected p53 and HER-21neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. // Cancer. 1997. — Vol. 79. — N 11. — P. 2147−2153.
- Averette H.E., Nguyen H.N. The role of prophylactic oophorectomy in cancer prevention. // Gynecol. Oncol. 1994. — Vol. 55. — N 3. — P. 38−41.
- Awakumov G.V., Zhuk N.I., Strelchonok O.A. Biological function of the carbohydrate component of the human sex steroid-binding globulin. // Bio-chem. USSR 1988. — Vol. 53. — P. 726−729.
- Вакег S.J., Fearon E.R., Nigro J.M. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. // Science. 1989. — Vol. 244. -P. 217−221.
- Berube D., Seralini G.E., Gagne R., Hammond G.L. Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17pl2—pl3). // Cytogenet. Cell. Genet. 1990. — Vol. 54. — N 1−2.-P. 65−67.
- Bocchinfuso W.P., Warmels-Rodenhiser S., Hammond G.L. Expression and differential glycolysation of human sex hormone-binding globulin by mammalian cell lines. // Mol. Endocrinol. 1991. — Vol. 5. — N 11. — P. 17 231 729.
- Bocchinfuso W.P., Lee W.M. et al. Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis. // Endocrinol. 1992. — Vol. 1. — P. 2331−2336.
- Bourne Т.Н., Campbell S., Reynolds K. et al. The potential role of serum С A 125 in an ultrasound-based screening programme for familial ovarian cancer. // Gynecol. Oncol. 1994. — Vol. 52. -N 3. — P. 379−385.
- Brody L.C., Biesecker B.B. Breast cancer susceptibility genes BRCA1 and BRCA2. // Medicine (Baltimore) 1998. — Vol. 77. — N 3. — P. 208−226.
- Bruning P.F., Bonfrer J.M.C., Hart A.M. Non-protein bound estradiol, sex hormone binding globulin, breast cancer and breast cancer risk. // Br. J. Cancer.- 1985. Vol. 51. — P. 479−484.
- Burke W., Daly M., Garber J. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. BRCA1 and BRCA 2. // JAMA. 1997. — Vol. 227. — P. 997−1003.
- Butzow T.L., Kettel L.M., Yen S.S. Clomiphene citrate reduces serum insulin-like growth factor 1 and increases sex hormone-binding globulin levels in women with polycystic ovary. // Fertil. Steril. 1995. — Vol. 63. — N 6. — P. 1200−1203.
- Carter G.D., Holland S.M., Alaghband-Zaden J. et al. Investigation of hirsutism: testosteron is not enough. // Ann. Clin. Biochem. 1983. — Vol. 20. -N5.-P. 262−263.
- Castelo-Branco C., Martinez de Osaba M.J., Fortuny A. et al. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. // J. Reprod. Med. 1995. — Vol. 40,-N8.-P. 556−560.
- Cornelisse M.M., Bennett P.E., Christiansen M. et al. Sex hormone-binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditions. // Clin. Chim. Acta. 1994. — Vol. 225. — N 2. — P. 115−121.
- Dachs G.U., Dougherty G.J., Stratford L.J., Chaplin D.J. Targeting gene therapy to cancer: A review. // Oncology Research. 1997. — Vol. 9. — P. 313−325.
- Dibbelt L., Knuppen R., Jutting G. et al. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. // Contraception. 1991, — Vol. 43.-N l.-P. 1−22.
- Dorum A., Kristensen G.B., Abeler V.M., Tropre C.G., Muller P. Early detection of familial ovarian cancer. // Eur. J. Cancer. 1996. — Vol. 32A.-N 10.-P. 1645−1651.
- Dowsett M., Attree S.L., Virdee S.S. et al. Oestrogen-related changes in sex-hormone-binding globulin levels during normal and gonadotropin-stimulated menstrual cycles. // Clin. Endocrinol. 1985. — Vol. 23. — P. 303 312.
- Dunlop M.G. Science, medicine and the future: colorectal cancer. Clinical review. // BMJ. 1997. — Vol. 314. — P. 1882.
- Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both teststeron-binding globulin and corticosteroid-binding globulin in human plasma. // J. Clin. Endocrinol. Metab. -1981.-Vol. 53.-N l.-P. 58−68.
- Easton D.F., Ford D., Bishop T. et al. Breast and ovarian cancer incidence in BRCA1- mutation carries. // Am. J. Hum. Genet. 1995. — Vol. 56. -P. 265−271.
- Easton D.F., Steele L., Fields P. et al. Cancer risks in two large breast cancer families linked to BRCA 2 on chromosome 13q 12−13. // Am. J. Hum. Genet. 1997. — Vol. 61. — P. 120−128.
- Eden J.A., Bush Т., Nano S. et al. A case-control study of combined continious estrogen-progestin replacement therapy among women with a personal history of breast cancer. // Menopause. 1995. — Vol. 2. — P. 67−72.
- Eeles R.A., Tan S., Wiltshaw E. et al. Hormone replacement therapy and survival after surgery for ovarian cancer. // BMJ. 1991. — Vol. 302. — P. 259−262.
- Eisinger F., Alby N., Bremond A. et al. Recommendations for medical management of hereditary breast and ovarian cancer. // Ann. Oncol. 1998. -Vol. 9.-N9.-P. 939−950.
- Eltabbakh G.H., Piver M.S., Hempling R.E. et al. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. // Gynecol. Oncol. 1997. — Vol. 66. — N 1. — P. 103−107.
- Erdmann D., Schindler E.M., Schindler A.E. Ovarian suppression with Diane 35/50. // Geburtshilfe Frauenheilkd. 1994. — Vol. 54. — N 11. — P. 627−633.
- Ernster V.L., Wrench M.R., Petrakis N.L. et al. Benign and malignant breast disease: initial study results of serum and breast fluid analysis of endogenous estrogens. // J. Natl. Cancer. Inst. 1987. — Vol. 79. — P. 949−960.
- Fathalla M.F. Incessant ovulation a factor in ovarian neoplasia. // Lancet.-1971.-Vol. 17.-P. 163.
- Feigelson H.S., Coetzee G.A., Kolonel L.N. et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. // Cancer. Res. 1997. -Vol. 57.-P. 1063−1075.
- Fentiman I.S. Prophylactic mastectomy, deliverance or delution? // BMJ.- 1998,-Vol. 317-P. 1402−1403.
- Fisher В., Constantino J.P., Wickerham D.L. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. // J. Natl. Cancer. Inst. 1998. — Vol. 90. — N 18. — P. 1371−1388.
- Fishman J., Bradlow H.L., Fukushima D.K. et al. Abnormal estrogen conjugation in women at risk for familial breast cancer at the periovulatory stage of the menstrual cycle. // Cancer. Research. 1983. — Vol. 43. — P. 1884−1890.
- FitzGerald M.G., MacDonald D.J., Kramer M. et al. Germ-tine BRCA 1 mutations in Jewish and non-Jewish women with early onset breast cancer. // Nat. Engl. J. Med. 1996. — Vol. 334. — P. 143−146.
- Fonseca M.E., Mason M., Ochoa R. et al. Changes in molecular forms of sex hormone-binding globulin during menstrual cycle and menopause. // Gynecol. Obstet. Мех. 1996. — Vol. 64. — P. 508−516.
- Ford D., Easton D.F., Peto J. Estimates of the gene frequency of BRCA 1 and its contribution to breast and ovarian cancer incidence. // Am. J. Hum. Genet. 1995. — Vol. 57. — P. 1457−1462.
- Ford D., Easton D.F., Stratton M. et al. Genetic heterogenity and penetrance analysis of BRCA 1 and BRGA 2 genes in breast cancer families. // Am. J. Hum. Genet. 1998. — Vol. 62. — P. 676−689.
- Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms deso-gestrel. // Contraception. 1995. — Vol. 51. — N 1. — P. 3−12.
- Fortunati N., Fissore F., Fazzari A. et al. Sex steroid binding protein interacts with a specific receptor on human premenopausal endometrium membrane. modulating effect of estradiol. // Steroids. 1991. — Vol. 56. — P. 341 346.
- Frank T.S., Manley S.A., Olopade O.l. et al. Sequence analysis of BRCA 1 and BRCA 2. correlation of mutations with family history and ovarian cancer risk. // J. Clin. Oncol. 1998. — Vol. 16. — N 7. — P. 2417−2425.
- Gallion H.H., Guarino A., DePriest P.D. et al. Evidence of unifocal origin in familial ovarian cancer. // Am. J. Obstet. Gynecol. 1996. — Vol. 174. — N 4. — P. 1102−1106- discussion: P. 1106−1108.
- Gershagen S., Henningsson K., Fernlund P. Subunits of human sex hormone binding globulin. // J. Biol. Chem. 1987. — Vol. 262. — N 17. — P. 8430−8437.
- Godard В., Foukes W.D., Provencher D. et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. // Am. J. Obstet. Gynecol. 1998. — Vol. 179. — N 2. — P. 403−410.
- Goldberg J.M., Piver M.S., Jishi M.F., Blumenson L. Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. // Gynecol. Oncol. 1997. — Vol. 66. — N 1. — P. 3−9.
- Goldin B.R., Woods M.N., Spiegelman D.L. et al. The effect of dietary of fat and fiber on serum estrogen concehtrations in premenopausal women under controlled dietary conditions. // Cancer. 1994. — Vol. 74. — Suppl. 3. -P. 1125−1131.
- Greenman J., Mohammed S., Ellis D. et al. Identification of missense and truncating mutations in BRCA 1 gene in sporadic and familial breast and ovarian cancer. // Genes Chromosomes Cancer. 1998. — Vol. 21. — N 3. — P. 244−249.
- Haffher S.M. Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. // Horm. Res. 1996. — Vol. 45. -N3−5.-P. 233−237.
- Hammond G.L., Robinson P.A., Sugino H. et al. Physiochermical characteristics of human sex hormone-binding globulin: evidence for two identical subunits. // J. Steroid. Biochem. 1986. — Vol. 24. — N 4. — P. 815−824.
- Hammond G.L., Underhill D.A., Rykse H.M., Smith C.L. The human sex hormone binding globulin gene contains exons for androgen binding protein and two other testicular messenger RNAs. // Mol. Endocrinol. 1989. — Vol. 3. -P. 1869−1876.
- Hammond G.L., Bocchinfuso W.P., Orava M. et al. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. // Contraception. 1994. — Vol. 50. — N 4. — P. 301−318.
- Hammond G.L., Bocchinfuso W.P. Sex hormone-binding globulin/ androgen-bindlng protein: steroid-binding and dimerization domains. // J. Steroid. Biochem. Mol. Biol. 1995. — Vol. 53. — N 1−6. — P. 543−552.
- Hammond G.L., Bocchinfuso W.P. Sex hormone-binding globulin: gen organization and structure/function analysis. // Horm. Res. 1996. — Vol. 45,-N3−5.-P. 197−201.
- Hankinson S.E., Colditz G.A., Hunter D.J. et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. // Obstet. Gynecol. -1992, — Vol. 80.-P. 708−714.
- Hankinson S.E., Hunter D.J., Colditz G.A. et al. Tubal ligation, hysterectomy and risk of ovarian cancer: a prospective study. // JAMA. 1993. -Vol. 270.-P. 2813−2818.
- Hankinson S.E., Colditz G.A., Hunter D.J. et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. // Cancer. 1995. -Vol. 76.-P. 284−290.
- Heiss C.J., Sanborn C.F., Nichols D.L. et al. Association of body fat distribution, circulating sex hormones and bone density in postmenopausal women. // J. Clin. Endocrinol. Metab. 1995. — Vol. 80. — N 5. — P. 1591−1596.
- Hori Т., Takahashi E., Murata M. Nature of distamycin A-inducible fragile sites. // Cancer. Genet. Cytogenet. 1988. — Vol. 34. — P. 189−194.
- Hryb D.J., Khan M.S., Romas N.A., Rosner W. The control of the interaction of sex hormone-binding globulin with its receptor by steroids hormones. // J. Biol. Chem. 1990. — Vol. 265. — P. 6048−6054.
- Hulka B.S. Epidemiologic analysis of breast and gynecologic cancers. // Prog. Clin. Biol. Res. 1997 — Vol. 396. — P. 17−29.
- Jaquish C.E., Blangero J., Haffher S.M. et al. Quantative genetics of serum sex hormone-binding globulin levels in participants in the San Antonio Family Heart Study. // Metabolism. 1997. — Vol. 46. -N 9. — P. 988−991.
- Jishi M.F., ltnyre J.H., Oakley-Girvan J.A. et al. Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. // Cancer. 1995. — Vol. 76. — N 8. — P. 1416−1421.
- Jolly K.W., Malkin D., Douglass E.C. et al. Splice-site mutation of the p53 gene in a family with hereditaiy breast-ovarian cancer. // Oncogene. 1994. -Vol. 9.-N l.-P. 97−102.
- Kainz C. Early detection and preoperative diagnosis of ovarian carcinoma. // Wien. Med. Wochenschr. 1996. — Vol. 146. — N 1−2. — P.2−7.
- Kaplan E.J., Caputo T.A., Shen P.U. et al. Familial papillaiy serous carcinoma of the cervix, peritoneum and ovary: a report of the first case. // Gynecol. Oncol. 1998. — Vol. 70. — N 2. — P. 289−294.
- Karlan B.Y., Piatt L.D. Ovarian cancer screening. The role of ultrasound in early detection. // Cancer. 1995. — Vol. 76. — Suppl. 10. — P. 20 112 015.
- Kasprzak L., Foulkes W.D., Shelling A.N. Hereditaiy ovarian carcinoma. Clinical review. // BMJ. 1999. — Vol. 318. — ?. 786−789.
- Kaufman D.W., Kelly J.P., Welch W.R. et al. Noncontraceptive estrogen use and epithelial ovarian cancer. // Am. J. Epidemiol. 1989. — Vol. 30. -N6.-P. 1142−1151.
- Kerber R.A., Slattery M.L. The impact of family history on ovarian cancer risk. The Utah Population Database. // Arch. Inter. Med. 1995. — Vol. 155.-N9.-P. 905−912.
- Kerlan V., Nahoul K., Le Martelot M.T., Bercovici J.P. Longitudinal study of maternal plasma bioavailable testosterone and androstanedion glucuro-nide levels during pregnancy. // Clin. Endocrinol. (Oxf) 1994. — Vol. 40. — N 2.- P. 263−267.
- Kerlikowski K., Brown J.S., Grady D.G. Should women with familial ovarian cancer undergo prophylactic oophorectomy? // Obstet. Gynecol. 1992.- Vol. 80. P. 700−707.
- Key T.J., Pike M.C. The role of oestrogens and progestagen. Epidemiology and prevention of breast cancer. // Eur. J. Cancer. Clin. Oncol. 1988.- Vol. 24. P. 29−43.
- Key T.J. Studies in the epidemiology of sex hormones and cancer. // Diss. Abstr. Int. 1991. — Vol. 51. — N 8. — P. 3789.
- Knudson A.G. Hereditary cancers: from discovery to intervention. // J. Natl. Cancer. Inst. Monogr. 1995. — Vol. 17. — P. 5−7.
- Laloo F., Cochrane S., Bulman B. et al. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews. // J. Med. Genet. 1998. — Vol. 35. — N 1. — P. 10−12.
- Lancaster J.M., Carney M.E., Futreal P.A. BRCA 1 and BRCA 2. A genetic link to familial breast and ovarian cancer. // Medscape Women’s Health- 1997,-Vol. 2.-N2.-P. 7.
- Landis S.H., Murray Y., Bolden S. et al. Cancer statistics, 1998. // CA Cancer. J. Clin. 1998. — Vol. 48. — P. 6−29.
- Langdon S.P., Smyth J.F. Growth factors and ovarian cancer. // Endocrine-Related Cancer. 1998. — Vol. 5. — P. 283−291.
- Lauritzen C. Cancer risk under hormone therapy. // Ther. Umsch. -1994. Vol. 51. — N 1. — P. 755−766.
- Liede A., Tonin P.H., Sun C.C. et al. Is hereditary site-specific ovarian cancer a distinct genetic condition? // Am. J. Med. Genet. 1998. — Vol. 75. — P. 55−58.
- Ligtenberg M.J., Hogervorst F.B., Willems H.W. et al. Characteristics of small breast and ovarian cancer families with germline mutations in BRCA 1 and BRCA 2. // Br. J. Cancer. 1999. — Vol. 79. — N 9−10. — P. 14 751 478.
- Lippman M.E., Swain S.M. Endocrine-responsive cancers of humans. In: Wilson JD, Foster DW (eds.). Williams Textbook of Endocrinology, 8th edition. W.B. Saunders, Philadelphia, 1992. — P. 1577−1599
- Lipworth L., Adami H.O., Trichopoulos D. Serum steroid hormone levels, sex hormone-binding globulin and body mass index in the etiology of postmenopausal breast cancer. // Epidemiology. 1996. — Vol. 7. — N 1. — P. 96−100.
- Loukovaara M., Carson M., Adlercreutz H. Regulation of production and secretion of sex hormone-binding globulin in Hep G2 cell cultures by hormones and growth factors. // J. Clin. Endocrinol. Metab. 1995. — Vol. 80. — N 1. — P. 160−164.
- Lynch H.T., Lynch P.M. Tumor variations in the cancer family syndrome: ovarian cancer. // Amer. J. Surg. 1979. — Vol. 138. — N 3. — P. 439 442.
- Lynch H.T., Albano W.A., Black L. et al. Familial excess of cancer of the ovary and other anatomic sites. // JAMA. 1981. — Vol. 5. — P. 245−261.
- Lynch H.T., Albano W.A., Neieck J.J. et al. Genetics biomark-ers and control of breast cancer: a review. // Cancer. Genet. Cytogenet. 1984. -Vol. 13.-N 1,-P. 43−92.
- Lynch H.T., Marcus J.F., Watson P., Lynch J.F. Familial and hereditary breast cancer. // Endocrine-Related Cancer. 1989. — Vol. 15. — P. 915.
- Mackley S.E., Creasman W.T. Ovarian cancer screening. // J. Clin. Oncol. 1995. — Vol. 13. — P. 783−793.
- MacMachon В., Tricopoulos D., Brown J. et al. Age at men-arche, urinary estrogens and breast cancer risk. // Int. J. Cancer. 1982. — Vol. 30,-N4.-P. 424−431.
- Matias-Guiu X., Prat J. Molecular pathology of ovarian carcinomas. // Virchows. Arch. 1998. — Vol. 433. — N 2. — P. 103−111.
- McKusik V.A. Mendelian inheritance in man: a catalog of human genes and genetic disorders. 1 led. — Baltimore: John Hopkins' University Press, 1994. — 234 p.
- Mercier-Bodard C., Baulieu E.E. Hormonal control of SBP in human hepatoma cells. // J. Steroid. Biochem. 1986. — Vol. 24. — N 2. — P. 443−448.
- Meyer S., Brumm C., Stegner H.E., Sinnecker G.H. Intracellular sex hormone-binding globulin (SHBG) in normal and neoplastic breast tissue -an additional marker for hormone dependency? // Exp. Clin. Endocrinol. -1994. Vol. 102. — N 4. — P. 334−340.
- Misao R., Hori M., Ichigo S. et al. Levels of sex hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG) messenger ribonucleic acid (mRNAs) in ovarian endometriosis. // Reprod. Nutr. 1995. -Vol. 35.-N2.-P. 155−165.
- Misao R., Nakanishi Y., Fujimoto J. et al. Expression of sex hormone-binding globulin mRNA in uterine cervical cancers. // Tumor. Biol. -1997.-Vol. 18.-N1.-P. 6−12.
- Misao R., Nakanishi Y., Fujimoto J., Tamaya T. Expression of sex hormone-binding globulin exon-7 splicing variant messenger RNA in human uterine endometrial cancers. // Cancer. Res. 1997. — Vol. 57. — N 24. — P. 5579−5583.
- Misao R., Nakanishi Y., Fujimoto J. et al. Dominant expression of sex hormone-binding globulin exon-7 splicing variant over wild-type mRNA in human ovarian cancers. // Int. J. Cancer. 1998. — Vol. 77. — N 6. — P. 828 832.
- Misao R., Fujimoto J., Nakanishi Y., Tamaya T. Localization of sex hormone binding globulin mRNA expression in human uterine endometrium. // Gynecol. Endocrinol. 1997. — Vol. 11. — N 1. — P. 1−4.
- Moore J.W. Clark G.M., Hoare S.A. et al. Binding of oestradiol to blood proteins and aetiology of breast cancer. // Int. J. Cancer. 1986. — Vol. 38. — P. 625−630.
- Moore J.W., Bulbrook R.D. The epidemiology and function of sex hormone binding globulin. // Oxford Rev. Reproductive Biol. 1988. — Vol. 10. — P. 3−4.
- Moore K.H., Bertman K.A., Gomes R.R. et al. Sex hormone binding globulin mRNA in human breast cancer: detection in cell lines and tumor samples. // J. Steroid. Biochem. Mol. Biol. 1996. — Vol. 59. — N 3−4. — P. 297 304.
- Moore M.M. The role of specialized genetic councelling for the patient at risk for breast cancer. // Cancer. Control: JMCC. 1998. — Vol. 5. -Suppl. 3. — P. 19−20.
- Mushayandebvu Т., Castracane V.D., Gimpel Т. et al. Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. // Fertil. Steril. 1996. — Vol. 65. — N 4. — P. 721−723.
- Nagai N. Evaluation of prognostic factors in gynecological cancer examined by molecular biological study. // Gan To Kagaku Ryoho. 1996. -Vol. 23.-N8.-P. 1004−1009.
- Narod S.A., Ford D., Devilee P. et al. An evaluation of genetic heterogenity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. // Am. J. Hum. Genet. 1995. — Vol. 56. — N 1. — P. 254−256.
- Narod S.A., Risch H., Moslehi R. et al. Oral contraceptives and the risk of hereditary ovarian cancer. // Nat. Engl. J. Med. 1998. — Vol. 339. -P. 424−428.
- O’Brien M.E., Dowsett M., Fryatt I., Wiltshaw E. Steroid hormone profile in postmenopausal women with ovarian cancer. // Eur. J. Cancer. -1994. Vol. 30A. — N 4. — P. 442−445.
- Okamura S., Koyama K., Miyoshi Y. et al. Novel germline mutations of hMSH2 in patient with hereditary nonpolyposis colorectal cancer (HNPCC) and in a patient with six primary cancers. // J. Hum.Genet. 1998. -Vol. 43. -N2. — P. 143−145.
- Olsen J.H., Seersholm N., Boice J.D. et al. Cancer risk in close relatives of women with early-onset cancer a population-based incidence study. // Br. J. Cancer. — 1999. — Vol. 79. — N 3−4. — P. 673−679.
- Parkin D.M., Whelan S.L., Ferlay J. et al. Cancer incidence in five continents. Lyons: International Agency for Research on Cancer, 1997.
- Parmigiani G., Berry D., Aguilar O. Determinning carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. // Am. J. Hum. Genet. 1998. — Vol. 62. — N 1. — P. 145−158.
- Paterson J.W. BRCA1: a review of structure and putative functions. // Dis. Markers. 1998. — Vol.13. — N 4. — P. 261−274.
- Piver M.S., Goldberg J.M., Tsukada Y. et al. Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner Familial Ovarian Cancer Registry. // Eur. J. Gynecol. Oncol. 1996. — Vol.17. -N3.-P. 169−176.
- Porto C.S., Musto N.A., Bardin C.W., Phillips D.M. Binding of extracellular steroid binding globulin to membranes and soluble receptors from human breast cancer cells. // Endocrinol. 1992. — Vol. 130. — P. 2931−2936.
- Potischman N., Hoover R.N., Brinton L.A. et al. Case-control study of endogenous steroid hormones and endometrial cancer. // J. Natl. Cancer. Inst. 1996. — Vol. 88. — N 16. — P. 1127−1135.
- Power S., Bocchinfuso W., Pallesen M. et al. Molecular analyses of a human sex hormone-binding globulin variant: evidence for an additional carbohydrate chain. // J. Clin. Endocrinol. Metab. 1992. — Vol. 75. — N 4. — P. 1066−1070.
- Purdie D., Green A., Bain C. et al. Reproductive and other factors and risk of epithelial ovarian cancer. // Int. J.Cancer. 1995. — Vol. 62. — P. 678−684.
- Rannevik G., Jeppsson S., Johnell O. et al. A longitudinal study of the peri menopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. // Maturitas. 1995. — Vol. 21. — N 2. -P. 103−113.
- Risch H.A., Marrett L.D., Howe G.R. Parity, contraception, infertility and the risk of epithelial ovarian cancer. // Am. J. Epidemiol. 1994. -Vol. 140. — P. 585−597.
- Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. // Gynecol. Oncol. 1996. — Vol. 63. — P. 254−257.
- Rosner W., Aden D.P., Khan M.S. Hormonal influences on the secretion of steroid-binding proteins by a human hepatoma-derived cell line. // J. Clin. Endocrinol. Metab. 1984. — Vol. 59. — P. 806−808.
- Rosner W. The functions of corticosteroids binding globulin and sex hormone binding globulin. Recent advances. // Endocr. Rev. 1990. — Vol. 11. — P. 80−89.
- Rosner W., Hryb D.J., Khan M.S. et al. Sex hormone-binding globulin: anatomy and physiology of a new regulatory system. // J. Steroid. Bio-chem. Mol. Biol. 1991. — Vol. 40. — N 4−6. — P. 813−820.
- Rubin S.C., Benjamin I., Behbakht K. et al. Clinical and pathological features of ovarian cancer in women with germ line mutations of BRC A 1. // Nat. Engl. J. Med. 1996. — Vol. 335. — N 19. — P. 1413−1416.
- Rudberg S., Persson B. Indications of low sex hormone binding globulin (SHBG) in young females with type 1 diabetes and an independent association to microalbuminuria. // Diabet. Med. 1995. — Vol. 12. — N 9. — P. 816−822.
- Schrap D., Kuntz K.M., Garber J.E. et al. Decision analysis: efects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 gene mutations. // N. Engl. J. Med. 1997. -Vol. 336.-P. 1465−1471.
- Schwartz P.E. Prophylactic oophorectomy for the prevention of epithelial ovarian cancer. // Eur. Menopause. J. 1997. — Vol. 4. — N 3. — P. 105−115.
- Scully R., Chen J., Plug A. et al. Association of BRCA 1 wuth rad 51 in mitotic and meiotic cells. // Cell. 1997. — Vol. 88. — P. 265−275.
- Simpson B.J., Langdon S.P., Rabiasz G.J. et al. Estrogen regulation of transforming growth factor-a in ovarian cancer. // J. Steroid. Biochem. Mol. Biol. 1998. — Vol. 64. — P. 137−145.
- Smigel K. Breast cancer prevention trial shows major benefit, some risk. // J. Natl. Cancer. Inst. 1998. — Vol. 0. — P. 647−648.
- Sodergard R., Bachstrom Т., Shanbhag V., Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17(5 to human plasma proteins at body temperature. // J. Steroid. Biochem. 1982. -Vol. 16.-P. 801−810.
- Thomas D.B., Persing J.P., Hutchinson W.B. Exogenous estrogens and other risk factors for breast cancer in women with bening breast diseases. // JNCI. 1982. — Vol. 69. — N 5. — P. 1017−1025.
- Thompson W.D. Genetic epidemiology of breast cancer. 11 Cancer. 1994. — Vol. 74. — Suppl. 1. — P. 279−287.
- Tobacman J.K., Green M.H., Tucker M.A. et al. Intraabdominal canceromatosis after prophylactic oophorectomy in ovarian-cancer-prone families. // Lancet. 1982. — ii: 795−797.
- Toniolo P.G., Koenig K.L., Pastemack B.S. et al. Reliability of measurements of total, protein-bound and unbound estradiol in serum. // Cancer. Epidemiol. Biomarkers. Prev. 1994. — Vol. 3. — N 1. — P. 47−50.
- Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A. et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. // J. Natl. Cancer. Inst. 1995. — Vol. 87. — N 3. — P. 190−197.
- Udoff L., Langenberg P., Adashi E.Y. Combined continuous hormone replacement therapy. A critical review. // Obstet. Gynecol. 1995. -Vol. 86. — P. 306−316.
- Van Baelen H., Convents R., Cailleau J., Heyns W. Genetic variation of human sex hormone-binding globulin: evidence for a world-wide bi-allelic gene. // J. Clin. Endocrinol. Metab. 1992. — Vol. 75. — N 1. — P. 135 139.
- Wiegratz I., Jung-Hoffmann C., Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. // Contraception. 1995. — Vol. 51-N6. -P. 341−346.
- Zaridze D., Kushlinskii N., Moore J.M. et al. Endogenous plasma sex hormones in pre- and postmenopausal women with breast cancer: results from a case-control study in Moscow. // Europ. J. Cancer. Prevent. 1992. -Vol.1.-P. 225−230.